An international team of scientists, including those at the
Translational Genomic Research Institute (TGen), have discovered new
avenues of potential treatments for a rare and deadly cancer known as
Adrenocortical Carcinoma, or ACC.
"This is one of the most comprehensive genomic characterizations ever
done of this rare tumor type," said Dr. Timothy Whitsett, an Assistant
Professor in TGen's Cancer and Cell Biology Division, and one of the
study's authors. "This study should provide rationale and validation for
new therapeutic strategies and clinical studies, providing potentially
better treatments for ACC patients." The study is part of The Cancer Genome Atlas (TCGA), a program overseen
by the National Institutes of Health (NIH) that aims to generate
comprehensive, multi-dimensional maps of the key molecular changes in
major types of cancer.
The ACC study examined 91 tumor samples from six countries across four continents, providing a global look at this disease.
One of the major findings of this study is the identification of a
third class, or subtype, of ACC. The study showed that the three
subtypes of ACC hold significantly different outcomes for patients,
and, based on their distinct molecular biomarkers, could help determine
the best course of treatment for each patient.
"Clinical implementation of this three-class grading system would represent a true advance for patient care."
No comments:
Post a Comment